ABBOTT LABORATORIES Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
ABBOTT LABORATORIES (ABT) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $13.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-04-29
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-03-31 was $13.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was -$565.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was $11.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-06-30 was -$26.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$610.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was -$765.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was -$117.00M.
- ABBOTT LABORATORIES other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$1.18B.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-03-31 | $13.00M 10-Q · filed 2026-04-29 | -$552.00M derived: sum of 2 quarters · filed 2026-04-29 | -$541.00M derived: sum of 3 quarters · filed 2026-04-29 | -$567.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | -$565.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$554.00M derived: sum of 2 quarters · filed 2026-02-20 | -$580.00M derived: sum of 3 quarters · filed 2026-02-20 | -$610.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $11.00M 10-Q · filed 2025-10-29 | -$15.00M derived: sum of 2 quarters · filed 2025-10-29 | -$45.00M 10-Q · filed 2025-10-29 | -$785.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | -$26.00M 10-Q · filed 2025-07-30 | -$56.00M 10-Q · filed 2025-07-30 | -$796.00M derived: sum of 3 quarters · filed 2026-04-29 | -$810.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | -$30.00M 10-Q · filed 2026-04-29 | -$770.00M derived: sum of 2 quarters · filed 2026-04-29 | -$784.00M derived: sum of 3 quarters · filed 2026-04-29 | -$791.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$740.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$754.00M derived: sum of 2 quarters · filed 2026-02-20 | -$761.00M derived: sum of 3 quarters · filed 2026-02-20 | -$765.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | -$14.00M 10-Q · filed 2025-10-29 | -$21.00M derived: sum of 2 quarters · filed 2025-10-29 | -$25.00M 10-Q · filed 2025-10-29 | -$155.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$7.00M 10-Q · filed 2025-07-30 | -$11.00M 10-Q · filed 2025-07-30 | -$141.00M derived: sum of 3 quarters · filed 2026-02-20 | -$132.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$4.00M 10-Q · filed 2025-04-30 | -$134.00M derived: sum of 2 quarters · filed 2026-02-20 | -$125.00M derived: sum of 3 quarters · filed 2026-02-20 | -$119.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | -$130.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$121.00M derived: sum of 2 quarters · filed 2026-02-20 | -$115.00M derived: sum of 3 quarters · filed 2026-02-20 | -$117.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $9.00M 10-Q · filed 2024-10-31 | $15.00M derived: sum of 2 quarters · filed 2024-10-31 | $13.00M 10-Q · filed 2024-10-31 | -$992.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $6.00M 10-Q · filed 2024-07-31 | $4.00M 10-Q · filed 2024-07-31 | -$1.00B derived: sum of 3 quarters · filed 2025-02-21 | -$1.06B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$2.00M 10-Q · filed 2024-05-02 | -$1.01B derived: sum of 2 quarters · filed 2025-02-21 | -$1.06B derived: sum of 3 quarters · filed 2025-02-21 | -$1.12B derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$1.00B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$1.06B derived: sum of 2 quarters · filed 2025-02-21 | -$1.11B derived: sum of 3 quarters · filed 2025-02-21 | -$1.18B 10-K · filed 2025-02-21 |
| 2022-09-30 | -$56.00M 10-Q · filed 2023-11-01 | -$110.00M derived: sum of 2 quarters · filed 2023-11-01 | -$172.00M 10-Q · filed 2023-11-01 | -$1.16B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | -$54.00M 10-Q · filed 2023-08-03 | -$116.00M 10-Q · filed 2023-08-03 | -$1.11B derived: sum of 3 quarters · filed 2024-02-16 | -$1.18B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | -$62.00M 10-Q · filed 2023-05-04 | -$1.05B derived: sum of 2 quarters · filed 2024-02-16 | -$1.13B derived: sum of 3 quarters · filed 2024-02-16 | -$1.18B derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | -$990.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | -$1.07B derived: sum of 2 quarters · filed 2024-02-16 | -$1.12B derived: sum of 3 quarters · filed 2024-02-16 | -$1.20B 10-K · filed 2024-02-16 |
| 2021-09-30 | -$78.00M 10-Q · filed 2022-11-01 | -$126.00M derived: sum of 2 quarters · filed 2022-11-01 | -$211.00M 10-Q · filed 2022-11-01 | $242.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | -$48.00M 10-Q · filed 2022-08-02 | -$133.00M 10-Q · filed 2022-08-02 | $320.00M derived: sum of 3 quarters · filed 2023-02-17 | $292.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$85.00M 10-Q · filed 2022-05-03 | $368.00M derived: sum of 2 quarters · filed 2023-02-17 | $340.00M derived: sum of 3 quarters · filed 2023-02-17 | $303.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $453.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $425.00M derived: sum of 2 quarters · filed 2023-02-17 | $388.00M derived: sum of 3 quarters · filed 2023-02-17 | $331.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | -$28.00M 10-Q · filed 2021-11-03 | -$65.00M derived: sum of 2 quarters · filed 2021-11-03 | -$122.00M 10-Q · filed 2021-11-03 | $772.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | -$37.00M 10-Q · filed 2021-08-04 | -$94.00M 10-Q · filed 2021-08-04 | $800.00M derived: sum of 3 quarters · filed 2022-02-18 | $769.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | -$57.00M 10-Q · filed 2021-05-05 | $837.00M derived: sum of 2 quarters · filed 2022-02-18 | $806.00M derived: sum of 3 quarters · filed 2022-02-18 | $780.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $894.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $863.00M derived: sum of 2 quarters · filed 2022-02-18 | $837.00M derived: sum of 3 quarters · filed 2022-02-18 | $814.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | -$31.00M 10-Q · filed 2020-11-04 | -$57.00M derived: sum of 2 quarters · filed 2020-11-04 | -$80.00M 10-Q · filed 2020-11-04 | -$106.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | -$26.00M 10-Q · filed 2020-07-29 | -$49.00M 10-Q · filed 2020-07-29 | -$75.00M derived: sum of 3 quarters · filed 2021-02-19 | -$97.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | -$23.00M 10-Q · filed 2020-04-29 | -$49.00M derived: sum of 2 quarters · filed 2021-02-19 | -$71.00M derived: sum of 3 quarters · filed 2021-02-19 | -$132.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$48.00M derived: sum of 2 quarters · filed 2021-02-19 | -$109.00M derived: sum of 3 quarters · filed 2021-02-19 | -$132.00M 10-K · filed 2021-02-19 |
| 2018-09-30 | -$22.00M 10-Q · filed 2019-10-31 | -$83.00M derived: sum of 2 quarters · filed 2019-10-31 | -$106.00M 10-Q · filed 2019-10-31 | $223.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | -$61.00M 10-Q · filed 2019-07-31 | -$84.00M 10-Q · filed 2019-07-31 | $245.00M derived: sum of 3 quarters · filed 2020-02-21 | $222.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | -$23.00M 10-Q · filed 2019-05-01 | $306.00M derived: sum of 2 quarters · filed 2020-02-21 | $283.00M derived: sum of 3 quarters · filed 2020-02-21 | $254.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $329.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $306.00M derived: sum of 2 quarters · filed 2020-02-21 | $277.00M derived: sum of 3 quarters · filed 2020-02-21 | $243.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | -$23.00M 10-Q · filed 2018-10-31 | -$52.00M derived: sum of 2 quarters · filed 2018-10-31 | -$86.00M 10-Q · filed 2018-10-31 | $226.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | -$29.00M 10-Q · filed 2018-08-01 | -$63.00M 10-Q · filed 2018-08-01 | $249.00M derived: sum of 3 quarters · filed 2019-02-22 | $234.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | -$34.00M 10-Q · filed 2018-05-02 | $278.00M derived: sum of 2 quarters · filed 2019-02-22 | $263.00M derived: sum of 3 quarters · filed 2019-02-22 | $310.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | $312.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $297.00M derived: sum of 2 quarters · filed 2019-02-22 | $344.00M derived: sum of 3 quarters · filed 2019-02-22 | $326.00M 10-K · filed 2019-02-22 |
| 2016-09-30 | -$15.00M 10-Q · filed 2017-11-02 | $32.00M derived: sum of 2 quarters · filed 2017-11-02 | $14.00M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $47.00M 10-Q · filed 2017-08-02 | $29.00M 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | -$18.00M 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | -$252.00M 10-K · filed 2018-02-16 | |||
| 2014-12-31 | $917.00M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |